Vogenx Inc.
VOGXHealthcare|Biotechnology|US
$17.45
-0.78 (-4.28%)
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07760961 Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia | Postbariatric Hypoglycemia | P2 | Recruiting | 36 | RCT, Double-blind | Mizagliflozin 5 mg, Mizagliflozin 10 mg, Placebo |
| NCT05721729 Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions | Postbariatric Hypoglycemia | P2 | Completed | 15 | RCT, Double-blind | Mizagliflozin, Placebo |
| NCT05541939 Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects | Postbariatric Hypoglycemia | P2 | Completed | 9 | RCT, Open-label | Mizagliflozin |